‘BG Negev’ Raises $1M For Neurodegenerative Diseases Study

BG Negev Technologies and Applications, the technology transfer company of Ben Gurion University of the Negev, has raised $1 million from a US private equity fund, to develop therapies for neurodegenerative diseases. The funding will support a study conducted by the university’s Department of Immunology and Microbiology, which might be useful for prolonging lifespans for patients with diseases such as Amyotrophic Lateral Sclerosis (ALS). View and share